



Policy Number: MP.126.MPC
Last Review Date: 05/19/2022
Effective Date: 06/01/2022

MP.126.MPC Cell-Free Fetal DNA Test

Cell-free fetal DNA testing has been validated for screening for Trisomy 21, Trisomy 18 and Trisomy 13.

According to the American College of Obstetricians and Gynecologists (ACOG) and the Society for Maternal-Fetal Medicine, the test should be discussed and offered to all pregnant women.

Limitations

1. Patients whose cell-free DNA screening test results are not reported by the laboratory or are uninterpretable (a no-call test result) should be informed that test failure is associated with an increased risk of aneuploidy, receive further genetic counseling and be offered comprehensive ultrasound evaluation and diagnostic testing. Only one cell-free DNA testing will be covered per pregnancy. Only one screening modality will be covered per pregnancy.
2. In multifetal gestations (more than two), if a fetal demise, vanishing twin or anomaly is identified in one fetus, there is a significant risk of an inaccurate test result if serum-based aneuploidy screening or cell-free DNA is used.

Background

ACOG estimates that 6-11% of stillbirths and neonatal deaths result from aneuploidies (fetus with missing or extra chromosomes). Most aneuploidies involve the presence of an extra chromosome, also referred to as trisomy.

Down syndrome, which is most commonly caused by trisomy 21 (T21), is routinely evaluated as the standard of care for the majority of the 4 million women who give birth each year in the United States. Conventional screening tests typically involve measurement of blood serum markers in conjunction with ultrasound followed by recommendation for diagnostic invasive procedures for abnormal results from screening.

First trimester combined screening (FTS) and integrated screening (INT) have the best screening performance, yet still only have T21 detection rates of 82-87% and 88-95%, respectively, at false positive rates of 5%. Invasive testing with amniocentesis or CVS is highly accurate but has up to a 3% risk of procedure related miscarriage. The reported complication rates have come down in the last 10 years, but there is still some procedure-related risk.

MP.126.MPC - Cell-Free Fetal DNA Test

Policy Number: MP.126.MPC

Last Review Date: 05/19/2022

Effective Date: 06/01/2022

A prenatal test that evaluates cell-free DNA (cfDNA) in maternal blood has been shown to be highly accurate, with T21 detection rates >99%, 98% detection rate for fetal trisomy 18 and 99% detection rate for fetal trisomy 13 with a combined false positive rate of 0.13%.

cfDNA testing, can detect more T21 cases and at the same time reduce unnecessary invasive procedures and in turn fewer procedure related fetal losses. cfDNA testing, when used as a follow-up test for an abnormal result from the FTS or INT screening test can spare the vast majority of the 5% of women with false positive results from undergoing invasive diagnostic testing. Any woman with an abnormal result from cfDNA test should undergo diagnostic testing by amniocentesis or chorionic villus sampling.

Currently, there are five cfDNA assays available in the United States: Harmony Prenatal Test, informaSeq, MaterniT21 PLUS, Panorama Prenatal Test, and Verifi Prenatal Test (the assays are listed in order of market entrance date).

Codes:

CPT Codes / HCPCS Codes / ICD-10 Codes	
Code	Description
CPT Codes	
81420	Fetal chromosomal aneuploidy (eg, trisomy 21, monosomy X) genomic sequence analysis panel, circulating cell-free fetal DNA in maternal blood, must include analysis of chromosomes 13, 18, and 21
81507	Fetal aneuploidy (trisomy 21, 18, and 13) DNA sequence analysis of selected regions using maternal plasma, algorithm reported as a risk score for each trisomy
ICD-10 codes covered if selection criteria are met:	
O35.1XX0-O35.1XX9	Maternal care for (suspected) chromosomal abnormality in fetus
O35.8XX0-O35.8XX9	Maternal care for other (suspected) fetal abnormality and damage
O35.9XX0-O35.9XX9	Maternal care for (suspected) fetal abnormality and damage, unspecified
O09.511-O09.519	Supervision of elderly primigravida
O09.521-O09.529	Supervision of elderly multigravida

MP.126.MPC - Cell-Free Fetal DNA Test

Policy Number: MP.126.MPC

Last Review Date: 05/19/2022

Effective Date: 06/01/2022

O28.0-O28.9

Abnormal findings on antenatal screening of mother

References

1. Caughey AB, Hopkins LM, Norton ME, Chorionic villus sampling compared with amniocentesis and the difference in the rate of pregnancy loss. *Obstet Gynecol.* 2006 Sep;108(3 Pt 1):612-616. <http://www.ncbi.nlm.nih.gov/pubmed/16946222>
2. <http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2600580/pdf/zpq20458.pdf>
3. Hayes GTE Overview. Cell-Free DNA (cfDNA) [Formerly NIPS, NIPT] Screening for Fetal Rare Autosomal Trisomies. Revised: 12/21/2021.
4. Hayes GTE Overview. Cell-Free DNA (cfDNA) [Formerly NIPS, NIPT] Screening for Fetal Chromosomal Copy Number Variants. Revised: 2/23/2022.
5. Hayes GTE Overview. Cell-Free DNA (cfDNA) [Formerly NIPS, NIPT] Screening for Fetal Sex Chromosome Aneuploidy. Oct 21, 2020. Revised: 9/23/2021.
6. Hayes GTE Report. Cell-Free DNA (cfDNA) [Formerly NIPS, NIPT] Screening for Fetal Trisomy 21, 18, and 13 in Low-Risk Women with Singleton Pregnancy. April 19, 2021.
7. Hayes GTE Report. Cell-Free DNA (cfDNA) [Formerly NIPS, NIPT] Screening for Fetal Trisomy 21, 18, and 13 in High-Risk Women. Feb 25, 2021.
8. Kollmann M, Haeusler M, Haas J, et al. Procedure-Related Complications after Genetic Amniocentesis and Chorionic Villus Sampling, *Ultraschall Med.* 2012 Jun 21. DOI: 10.1055/s-0032-1312939. <http://www.ncbi.nlm.nih.gov/pubmed/22723040>
9. National Institutes of Health, National Library of Medicine. Genetics Home Reference, Trisomy 13 Reviewed May 10, 2021. <http://ghr.nlm.nih.gov/condition/trisomy-13>
10. National Institutes of Health, National Library of Medicine. Genetics Home Reference: Trisomy 18, Reviewed May 10, 2021. <http://ghr.nlm.nih.gov/condition/trisomy-18>
11. National Institutes of Health, National Library of Medicine. Genetics Home Reference: Down Syndrome, Reviewed May 10, 2021. <http://ghr.nlm.nih.gov/condition/down-syndrome>
12. National Institutes of Health, National Library of Medicine. Medline Plus: Quadruple screen test. Updated May 4, 2021. <http://www.nlm.nih.gov/medlineplus/ency/article/007311.htm>
13. National Institutes of Health, National Library of Medicine. PubMed Health. A.D.A.M. Medical Encyclopedia, Amniocentesis. Updated May 4, 2021. <https://medlineplus.gov/ency/article/003921.htm>

MP.126.MPC - Cell-Free Fetal DNA Test

Policy Number: MP.126.MPC

Last Review Date: 05/19/2022

Effective Date: 06/01/2022

14. National Institutes of Health, National Library of Medicine. PubMed Health. A.D.A.M. Medical Encyclopedia: Chorionic Villus Sampling. Reviewed January 2019, <https://www.acog.org/Patients/FAQs/Prenatal-Genetic-Diagnostic-Tests#villus>
15. Scott F, Peters H, Boogert T, et al. The loss rates for invasive prenatal testing in a specialised obstetric ultrasound practice. Aust N Z J Obstet Gynaecol. 2002 Feb;42(1):55-58, <http://www.ncbi.nlm.nih.gov/pubmed/11926642>
16. Screening for Fetal Chromosomal Abnormalities: ACOG Practice Bulletin, Number 226 American College of Obstetricians and Gynecologists' Committee on Practice Bulletins—Obstetrics; Committee on Genetics; Society for Maternal-Fetal Medicine. <https://pubmed.ncbi.nlm.nih.gov/32804883/>

Disclaimer:

Maryland Physicians Care medical payment and prior authorization policies do not constitute medical advice and are not intended to govern or otherwise influence the practice of medicine. The policies constitute only the reimbursement and coverage guidelines of Maryland Physicians Care and its affiliated managed care entities. Coverage for services varies for individual members in accordance with the terms and conditions of applicable Certificates of Coverage, Summary Plan Descriptions, or contracts with governing regulatory agencies.

Maryland Physicians Care reserves the right to review and update the medical payment and prior authorization guidelines in its sole discretion. Notice of such changes, if necessary, shall be provided in accordance with the terms and conditions of provider agreements and any applicable laws or regulations.

These policies are the proprietary information of Maryland Physicians Care. Any sale, copying, or dissemination of said policies is prohibited.